AnaMar

#AnaMar #Autoimmune disease #European Medicines Agency #FDA #Fibrotic disease #Orphan drugs

Dual-action treatment for fibrotic disease secures orphan drug status

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and… Read More

#News #Regulatory

Respiratory system
#AnaMar #Clinical trial #Fibrosis #Lung disease #Phase I trial

Positive Phase I data for oral fibrosis treatment

AnaMar has announced positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies, for AM1476’s initial orphan indication in systemic sclerosis (SSc) characterised by lung and skin fibrosis. AM1476, a highly selective small molecule, delivered as an orally administered tablet,… Read More

#News